Moderna (MRNA)
(Delayed Data from NSDQ)
$46.83 USD
-3.45 (-6.86%)
Updated Nov 8, 2024 04:00 PM ET
After-Market: $46.85 +0.02 (0.04%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$46.83 USD
-3.45 (-6.86%)
Updated Nov 8, 2024 04:00 PM ET
After-Market: $46.85 +0.02 (0.04%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Zacks News
Moderna (MRNA) Stock Drops Despite Market Gains: Important Facts to Note
by Zacks Equity Research
Moderna (MRNA) concluded the recent trading session at $110.43, signifying a -1.38% move from its prior day's close.
Why Moderna (MRNA) Stock Price Was Up 9% on Monday
by Zacks Equity Research
Moderna (MRNA) surges amid initiation reports of a phase II/III study on Merck-partnered experimental cancer therapy to treat patients with cutaneous squamous cell carcinoma, a form of skin cancer.
Moderna (MRNA) Soars 8.7%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Moderna (MRNA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Company News for Feb 23, 2024
by Zacks Equity Research
Companies in The News Are: SNPS, MRNA, IDA, AMD
The Zacks Analyst Blog Highlights Moderna, RAPT Therapeutics, Iovance, Sarepta Therapeutics and Regeneron
by Zacks Equity Research
Moderna, RAPT Therapeutics, Iovance, Sarepta Therapeutics and Regeneron are included in this Analyst Blog.
Moderna (MRNA) Beats on Q4 Earnings & Sales, Reiterates View
by Zacks Equity Research
Moderna (MRNA) beats expectations for earnings and sales. Management reiterates guidance to record around $4 billion from product sales in 2024.
Biotech Stock Roundup: MRNA's Q4 Results, RAPT Down on Study Results & Other Updates
by Zacks Equity Research
Earnings from Moderna (MRNA) and pipeline update from RAPT are in focus in the biotech sector.
Moderna (MRNA) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Moderna (MRNA) delivered earnings and revenue surprises of 170.51% and 10.32%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Aquestive (AQST) to Report Q4 Earnings: Here's What to Expect
by Zacks Equity Research
Investor focus is likely to be on Aquestive Therapeutics' (AQST) updates regarding key pipeline candidate, Anaphylm Sublingual Film, on the fourth-quarter 2023 earnings call.
Biotech/Drug Stocks Q4 Earnings Due Feb 22: MRNA, BHC, NTLA, BMRN & More
by Ekta Bagri
Let us take a look at what's in store for biotech/drug stocks MRNA, BHC, NTLA, BMRN and ITCI, which are scheduled to report on Feb 22.
Why Earnings Season Could Be Great for Moderna (MRNA)
by Zacks Equity Research
Moderna (MRNA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Amphastar (AMPH) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Amphastar's (AMPH) revenues in the fourth quarter of 2023 are expected to have been driven by the sales of its pharmaceutical products.
Earnings Preview: Beam Therapeutics Inc. (BEAM) Q4 Earnings Expected to Decline
by Zacks Equity Research
Beam Therapeutics Inc. (BEAM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Moderna (MRNA) Gears Up for Q4 Earnings: Will It Top Estimates?
by Zacks Equity Research
Investors' focus will likely be on updates on Moderna's (MRNA) pipeline, especially its late-stage pipeline candidates, when it reports fourth-quarter earnings.
Can Rigel Pharmaceuticals (RIGL) Beat Q4 Earnings Estimates?
by Zacks Equity Research
Rigel Pharmaceuticals' (RIGL) Tavalisse tablet sales are expected to have risen in the fourth quarter, driven by demand growth.
Moderna (MRNA) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Moderna (MRNA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Exact Sciences (EXAS) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
Exact Sciences' (EXAS) revenues in the fourth quarter of 2023 are likely to have been driven by its flagship cancer screening tests, Cologuard and Oncotype DX.
5 Biotech Stocks Likely to Outpace Q4 Earnings Estimates
by Kinjel Shah
Let us look at some drug/biotech stocks, MRNA, BMRN, AMRN, NTLA and BEAM, which are poised to beat on fourth-quarter earnings.
Here's Why Moderna (MRNA) Gained But Lagged the Market Today
by Zacks Equity Research
The latest trading day saw Moderna (MRNA) settling at $85.95, representing a +0.68% change from its previous close.
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Y-mAbs Therapeutics, Inc. (YMAB) Moves 9.5% Higher: Will This Strength Last?
by Zacks Equity Research
Y-mAbs Therapeutics, Inc. (YMAB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Can Biogen (BIIB) Keep the Beat Streak Alive in Q4 Earnings?
by Zacks Equity Research
Biogen's (BIIB) sales in the fourth quarter are likely to have been hurt by lower sales of its multiple sclerosis drugs, while sales of Spinraza are likely to have risen.
Moderna (MRNA) Stock Slides as Market Rises: Facts to Know Before You Trade
by Zacks Equity Research
In the most recent trading session, Moderna (MRNA) closed at $99.30, indicating a -0.73% shift from the previous trading day.
AstraZeneca (AZN) to Report Q4 Earnings: Here's What to Expect
by Zacks Equity Research
Sales of AstraZeneca's (AZN) key drugs like Imfinzi and Farxiga are expected to have been boosted by approvals in new indications.
Gilead (GILD) Gears Up to Report Q4 Earnings: Whats in Store?
by Zacks Equity Research
Investors' focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports its fourth-quarter 2023 results.